Hi @Bouncing
The next trial that will start later this year, is an adaptive 2/3 trial for which the FDA has already advised they will consider accelerated approval at the 24 week mid trial results. This I understand is reliant on gaining Orphan Drug Designation status. The shelf life is also considerable so making a bulk batch will not go to waste.
Cheers
Hi @Bouncing The next trial that will start later this year, is...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $87.51M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 17.5¢ | $144.9K | 808.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 331391 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 183765 | 4 |
View Market Depth
| Last trade - 15.58pm 29/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |